DNER and hypertensive disorder: Emerging therapeutic targets with promise include histone deacetylation (directly with HDACi, or indirectly using NAD+ repletion), modulation of gut microbiome-derived mediators of hypertension and inflammation, and epigenetic modifiers including BET inhibitors and CDR132L.